assist reproduct servic infanc
erratum correct version publish august correct
share-pric relat estim base incorrect
share count tabl cover page figur
initi coverag jinxin fertil outperform rate
believ ar assist reproduct servic becom
popular china near-to-mid futur due govern concern
age popul late marriag age among young peopl well
increas dispos incom area underdevelop huge potenti
limit privat player due high entri barrier initi coverag
jinxin fertil target price outperform rate
boom china assist reproduct servic market huge
opportun use top-down method estim potenti
china ar market size roughli bneight-fold
current bn market size believ rise infertil rate
recommend infertil guidelin increas afford
three main drive forc ramp china ar market believ
lead ar hospit benefit higher market penetr
consolid
jinxin solid player high entri barrier market technolog
licenc main entri barrier new entrant ar market
jinxin achiev solid perform year oper
jinxin gain market share sichuan first-mov
advantag reproduc jinxin busi model proven
success acquisit shenzhen zhongshan hospit jinxin also
open oversea market medic believ build
global lead ar platform futur
valuat target price potenti upsid base
multi-stag discount cash flow dcf method weight averag cost
capit wacc perpetu growth target price well
justifi within industri averag
select medic servic compani risk target price
includ regulatori polici chang delay progress competit
number share mn
price month
price rel chart measur perform
china close
spot exchang rate
valuat metric
chg prev ep
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
good sold
profit tax
free cash flow firm
net chang cash
jinxin fertil lead assist reproduct servic ar
provid china three ar center includ chengdu
xinan shenzhen zhongshan us-bas rank third
sky valuat hk assum jinxin market
penetr sichuan guangdong rest china could reach
grey sky valuat hk assum jinxin market
penetr sichuan guangdong rest china could reach
price rel chart measur perform china
close
spot exchang rate
charl martineau univers toronto focu chart tabl
figur potenti ar market size china top-
method
figur jinxin fertil higher success rate
averag
actual new born popul
undeliv new born due infertil
market develop
figur revenu forecast jinxin fertil
ivf revenu china
note medic acquir jinxin decemb
figur valuat deriv dcf
npv cash-flow
npv tv
number share
jinxin data base cs model price august
bloomberg professionaltm servic compani credit suiss estim jinxin
charl martineau univers toronto china ar market
three main drive
advantag
strengthen
reproduc
model proven
success
tp
support dcf
model peer-
market huge opportun
ar becom popular china near-to-mid futur due
govern concern age popul late marriag age among young
peopl well increas dispos incom view use top-down method
estim potenti china ar market size roughli bn
eight-fold current bn market size rise infertil rate recommend
infertil guidelin increas afford three main drive forc
ramp china ar market also believ upgrad test-tub babi
technolog futur consolid china ar industri two opportun
benefit lead ar provid china
top tier ar hospit strong competit
high barrier
ar core sole busi jinxin fertil compani revenu gener
two channel self-own ar hospit manag ar hospit ivf
biggest revenu sourc account total revenu
year oper jinxin gain market share sichuan first-mov
advantag also earn good reput jinxin obtain licenc ivf
technolog result high entri barrier new entrant ar
market compani keep strengthen technolog edg continu
invest manag optimis
reach nation oversea market
reproduc jinxin busi model proven success acquisit
shenzhen zhongshan hospit complet ivf cycl
success rate account share guangdong ivf market
futur china compani target ar facil perform
ivf treatment cycl per year local recognis brand alreadi
possess convent ivf-et/icsi licenc compani also open oversea ivf
market acquisit medic us target high-end patient
seek ar abroad believ jinxin build global lead ar platform
initi outperform tp
initi coverag jinxin fertil outperform rate target price
potenti upsid target price calcul multi-stag
discount cash flow dcf method weight averag cost capit wacc
perpetu growth target price well justifi
within industri averag select medic servic
major invest risk view includ risk stricter regulatori polici risk
get renew licenc risk maintain reput risk progress
expect risk fiercer competit
tabl content
assist reproduct servic infanc
boom china assist reproduct servic market huge
top tier ar hospit strong competit high barrier
reach nation oversea market
initi outperform tp
tabl content
boom china assist reproduct servic market huge opportun
huge undevelop ar market china
three drive forc ramp ar
forese opportun fast-grow china ar
drive forc rise infertil rate china
drive forc ar clearli recommend infertil guidelin
drive forc ivf becom afford china
test-tub babi technolog huge upgrad potenti china
lead ar hospit benefit futur industri integr
top-tier ar hospit strong competit high barrier
ar domin revenu sourc
busi model focus
barrier secur compani lead posit ar
technolog licenc two main barrier alreadi built
continu invest strengthen technolog edg
reach nation oversea market
acquisit shenzhen zhongshan hospit success exampl
 compani key strategi china busi expans
domest expans acquir local lead privat ivf
tap oversea ar market
huge unmet need chines patient seek ivf servic oversea
acquisit medic open oversea market
synergi medic jinxin
initi outperform tp
sky/grey sky valuat
risk stricter regulatori polici
risk get renew licenc
risk progress
risk fiercer
sharehold corpor structur
holt view jinxin fertil group
market size
estim reach
bn
respect
servic market huge opportun
assist reproduct servic ar kind medic servic primarili use address
infertil includ artifici insemin test-tub babi technolog larg
exist infertil popul steadi increas infertil rate huge
unmet need ar china howev ar penetr rate china low
size ar provid still quit small impli huge upsid potenti china
huge undevelop ar market china
age popul later marriag age among young peopl becom
increas concern chines govern incent polici
brought sinc encourag young coupl deliv babi
figur histori popul control china
implement famili plan polici
only-child parent rural area deliv two babi
only-child parent urban area deliv two babi
one coupl child coupl deliv two babi
coupl deliv two babi
accord frost sullivan analysi ar market china enjoy rapid growth
bn bn repres compound-annual-growth-rate
market growth mainli driven increas infertil rate chines
govern birth incent polici ar penetr china still quit low
compar us given increas afford accept
ar penetr rate market size estim reach bn
repres compound-annual-growth-rate
figur ar penetr rate china
method estim
potenti china
ar market size
roughli
current bn
use top-down method estim potenti china ar market size
roughli bn bn eight fold current bn market size
underdevelop view calcul method
number new-born china mn
consid infertil rate women attempt get pregnant
number babi could deliv due infertil mn
assum patient may tri ar least potenti market size
base research publish reproduct biolog endocrinolog
proport patient use ai test-tub babi technolog
china patient need averag cycl treatment use test-tub
averag price one ai one test-tub cycl
figur potenti ar market size top-down method china
actual new born popul
undeliv new born due
market develop
note zhou zehong et al epidemiolog infertil china populationbas studi bjog intern journal obstetr
gynecolog wahlberg ayo birth routin ivf china reproduct biomedicin societi on-line
china nation bureau statist credit suiss research
three drive forc ramp ar market
believ rise infertil rate recommend infertil guidelin
increas afford three main drive forc ramp china ar
drive forc rise infertil rate china
infertil defin world organ failur
achiev clinic pregnanc month regular unprotect sexual
intercours becom sever burden individu famili societi caus
recommend
three main
drive forc
ramp
charl martineau univers toronto infertil wide rang includ socio-econom factor lifestyl reproduct
histori childbear statu
figur preval infertil chang
figur percentag lead caus
women risk
pregnanc
among women
attempt becom
pregnant
ar recommend
updat
acog guidelin
base studi publish reproduct biolog endocrinolog preval
infertil rang develop countri
develop countri epidemiolog studi china show preval infertil
among women risk pregnanc infertil rate among
women attempt becom pregnant
nowaday due older age marriag higher educ level faster pace life
sever pollut preval infertil increas past
decad china compar data preval infertil china risen
current may hit
drive forc ar clearli recommend infertil guidelin
china patient may go gynecolog depart femal urolog
depart male first concern delay concept usual
lifestyl advic provid patient first assess infertil
diagnos infertil coupl receiv examin investig potenti
caus infertil male semen analysi use often ovul
disord tubal uterin abnorm need assess femal
patient medic surgeri may solv infertil problem howev around
coupl end assist reproduct patient refer assist
intern mainstream infertil guidelin publish nation institut
excel uk acog american colleg obstetrician
intracytoplasm sperm inject icsi recommend standard
treatment infertil suffici clinic evid higher number physician
may recommend ar patient base guidelin instruct flow
figur infertil patient flowchart nice guidelin
investig caus
assess manag
investig suspect tubal
medic manag male factor fertil problem
surgic manag male factor fertil problem
manag ejaculatori failur
ovarian stimul unexplain infertil
diagnos manag endometriosi
tubal uterin surgeri
nation institut excel infertil guidelin credit suiss research
drive forc ivf becom afford china
consid health mother offspr women china prefer
conceiv age year moreov infertil rate increas age
lead elev need ivf result women
strong payment abil repres largest group ivf user china
price ivf hospit around afford
chines famili one hand patient will use ivf usual well-
educ tri mani method final go ivf
hand concept import uniqu mean famili chines
cultur coupl get support whole famili result ivf patient
china less price-sensit care success rate resid
rise dispos incom healthcar spend ivf penetr rate keep
rise china
femal strong
repres largest
group ivf user
charl martineau univers toronto figur preval overal infertil
healthcar spend china
women year
nation bureau statist credit suiss research
forese opportun fast-grow china ar
test-tub babi technolog huge upgrad potenti china
one mostli use assist reproduct method ivf medic procedur
primarili use address infertil ivf technolog significantli develop
last year sinc first birth child ivf treatment england sinc
ivf evolv embryo transfer technolog latest cytoplasm transfer
technolog address differ patient need help physician increas
implant success rate less present
technolog china
huge upgrad
potenti area
technolog
figur evolv technolog test tube babi
process fertilis
egg combin
sperm outsid bodi
singl sperm cell inject
directli cytoplasm
diagnosi pgd
genet profil embryo
prior implant
inject small amount
cytoplasm egg fertil
women egg infertil
femal infertil due
fallopian tube slight
male infertil due sever
patient need use test-
parent genet diseas
femal infertil due defect
rmb china
licenc
howev adopt advanc ivf less china compar
develop market follow three reason
pgd/pg test-tub babi technolog wide use china
ar hospit china licenc perform pgd/pg pre-
implant genet diagnosis/screen technolog common us
thailand pgd/pg screen mani genet diseas embryo
implant improv success rate well health babi
chain broken
three part
success rate china lower us accord frost
sullivan report averag success rate ivf china vs us
differ mainli caus less experienc doctor rel old ivf
technolog use china
less matur ar legal environ china countri us
systemat law standard ar clarifi patient doctor right
clearli elimin mani legal problem ivf busi moreov
servic like surrogaci commerci egg/sperm donat total ban
china also hinder develop relev technolog
result test-tub babi technolog china still huge potenti upgrad
especi pgd/pg technolog provid get licenc may achiev
higher success rate revenu quickli compar penetr rate us
whole ar industri definit benefit evolv technolog
lead ar hospit benefit futur industri
ar industri valu chain broken follow three part
upstream includ manufactur medic devic vitro diagnost ivd
pharmaceut relat diagnos treatment infertil devic mainli
includ egg retriev needl embryo transfus cathet ar consum
pharmaceut mainli includ sexual hormon human chorion gonadotropin
hcg progesteron progestin etc
midstream includ intermediari agenc patient hospit
includ online/offlin pregnanc health manag servic provid cross-
border medic supplier introduc oversea ar domest patient
compani provid inform patient help contact oversea
hospit receiv commiss form patient hospit
downstream includ domest oversea ar hospit directli
provid ar treatment infertil patient
figur valu chain china ar industri
center peke univers third hospit xinan hospit own jinxin fertil
import
player entir
valu chain
benefit
develop
downstream lead ar hospit import player entir valu
chain benefit develop industri compar
player due follow reason
hospit patient main entranc ar industri success rate
patient first consid choos ar provid lead hospit usual
higher success rate gain valuabl experi perform
higher number ivf cycl moreov hospit strong bargain power
compar upstream compani sinc doctor influenc patient
decis upstream midstream compani reli highli hospit
patient spend money hospit other whole ivf
treatment process patient pay total cost ar hospit howev
spent drug physic examin hospit also
price power patient may price sensit especi
figur patient spend detail ar
figur number class hospit ivf
hosptal ivf licens
china ivf market still
highli fragment
china ivf market highli fragment total ivf cycl
perform china top top ivf provid perform
total cycl respect three hospit perform cycl
top hospit perform cycl similar us market china ivf market
also highli fragment fierc competit
figur top hospit china ivf cycl
market share ivf number
reproduct hospit affili shandong univers
reproduct center peke univers third hospit
shanghai ninth peopl hospit affili shanghai jiaotong univers
special licenc
need ivf
privat
special licenc need hospit want provid ivf servic strict
requir hospit hardwar technolog end ar
hospit own ivf licenc public hospit
charl martineau univers toronto privat hospit number public ivf hospit much privat hospit
mainli high requir hardwar ivf cycl
figur number differ ar technolog provid china
note hospit aih licenc suspend
leav room futur
view follow two reason explain ivf market fragment
nation health commiss encourag ar hospit geolog
evenli distribut base popul distribut
patient unwil receiv ivf treatment far home due rel long
result provinc may give rise lead ar hospit believ
featur industri benefit lead player provinc leav room
nation-wid consolid futur
charl martineau univers toronto jinxin fertil
advantag high
top-tier ar hospit strong
competit high barrier
jinxin rank number ivf cycl perform view besid
strong competit high market barrier critic long-term success
medic servic provid believ jinxin fertil compani uniqu competit
advantag high barrier ar industri
busi model focus ar
ar core sole busi jinxin fertil compani gener revenu
two channel self-own ar hospit manag ar hospit current
compani own three hospit one surgeri centr one laboratori global well
jointli manag one hospit chengdu hospit relev facil constitut
jinxin main ar network china us
figur ar facil own jinxin fertil
chengdu jinjiang matern child health hospit
oper
acquir
acquir
acquir
jointli manag
indirectli acquir
ar domin revenu sourc
ivf treatment biggest import revenu sourc jinxin account
total revenu three hospit oper
compani ai ivf icsi intracytoplasm sperm inject licenc china
total ivf cycl perform xinan hospit cycl shenzhen
zhongshan hospit revenu direct ivf treatment mn
mn balanc mn revenu xinan hospit
relev servic vip servic
ancillari servic includ gynecolog urolog intern medicin provid
shenzhen zhongshan hospit medic servic inherit pre-
acquisit expect remain stabl
figur compani revenu structur
addit self-own ar hospit compani two manag hospit
chengdu jinjiang hospit medic us one earliest ivf
hospit sichuan jinjiang hospit entri point jinxin fertil earli
develop stage sinc compani seek synergi joint-manag
jinjiang hospit collabor clinic diagnosi treatment scientif
research academ exchang personnel train collabor
gener manag incom compani also improv jinxin medic
servic level promot develop clinic reproduct embryolog nurs
gynecolog endocrinolog manag servic fee base scope
frequenc servic provid jinxin fertil base agreement
figur benefit jointli manag jinjiang hospit
situat quit differ come manag servic medic
california corpor practic medicin doctrin medic corpor
own oper physician medic indirectli control jinxin
manag sign agreement medic
oper profit acquisit decemb manag revenu
consolid jinxin financi report
figur estim revenu differ busi
rmb million
ivf revenu china
barrier secur compani lead posit
technolog licenc two main barrier alreadi built
jinxin fertil histori track back one longest
sichuan first-mov advantag creat signific opportun jinxin especi
licenc approv technolog sediment late comer enter sichuan market
hard overcom barrier establish earlier competitor like jinxin
chengdu xinan gynecolog hospit xinan hospit establish
receiv ivf licenc provid cycl highest sichuan
besid ar servic aid aih ivf-et icsi xinan hospit also provid
tradit chines medicin gynecolog androlog surgeri psycholog servic
vip client also get conveni privat servic hospit expand
servic qualiti capac xinan hospit recent move sq
new build februari increas hospit capac ivf
xinan hospit keep improv intern servic qualiti extern influenc
hospit use qualiti control system well
develop qualif manag system extern xinan hospit
sign assist reproduct technolog cooper agreement
hospit without ivf licenc sichuan provinc set xinan consult room
patient referr xinan account xinan patient
xinan hospit
largest ivf provid
charl martineau univers toronto figur new build chengdu xinan hospit
jinjiang hospit one
earliest ivf
centr sichuan
jinxin success rate
china higher
nation
averag hrc
success rate us
higher us
averag
compani also provid manag servic chengdu jinjiang matern
child health hospit jinjiang hospit ar centr sinc jinjiang hospit non-
profit specialti hospit establish ar centr receiv ivf licenc
one earliest ivf centr sichuan provinc jinjiang hospit provid aih
artifici insemin husband ivf-et icsi servic also experi
treat age patient prematur ovarian failur pof jinjiang hospit perform
around ivf cycl everi year accord manag agreement jinxin
fertil right charg manag fee revenu gener jinjiang
technolog long-term practic help make high success rate
success rate total clinic concept number/tot implant number wide
recognis index evalu ivf hospit jinxin fertil success rate china
reach compar nation averag us fertil success
rate reach higher us averag california averag
patient success rate determin factor choos ivf hospit
result higher success rate jinxin fertil set high bar ivf hospit
compet china market
figur jinxin fertil higher success rate averag
note medic acquir jinxin decemb
high success rate achiev compani well-establish lab/clin
practic experienc team physician led cso dr ling chi renown
embryologist compani establish sop embryon lab continu
charl martineau univers toronto year lead time
need establish
new ivf hospit
invest area reproduct immunolog increas success rate
howev divid medic team fertil physician sub-team
specialis focu address personalis need differ patient group elder
patient habitu abort patient etc within sub-team usual made one lead
three support physician support physician could get good train
lead physician ensur expans experienc medic team
licenc golden era gone scarciti stop new entrant
birth control nation polici last year recent eas
new hospit enter ar industri much difficult get licenc ten
year ago ar hospit china strong govern regul sinc
begin suppli ar hospit total control nation
health commiss design plan propos everi ar
hospit cover mn peopl actual becom rout map
industri develop develop ar hospit china experienc
follow three stage far
get approv ar hospit difficult due strict
regul ar hospit nationwid end
approv right ar hospit grant provinci
health commiss fast develop assist reproduct technolog
period number ar hospit china rose end
slow approv pace
hospit everi year requir qualifi institut becom much
figur number approv ar ivf hospit china
number ar hospit
nmuber ivf provid
privat hospit jinxin fertil get ivf licenc even difficult
time-consum public hospit strict requir ivf
hospit level employe abil oper qualiti meet requir high
fix capit invest stabl talent team need nearli imposs
new entrant without experi industri
figur requir ivf licenc applic
principl applic must class hospit approv
leader central laboratori clinic work must senior-level titl
ivf cycl success rate must reach certain standard
doctor technologist medic institut must meet criteria
 institut must complet ivf cycl per year success rate must first year second year
need pass verif everi two year
need hire trainer nhc-design ar train centr
ar equip requir
size institut must sq
believ licenc one core asset ar hospit new licenc
approv impli scarciti high
valu ivf licenc acquisit shenzhen zhongshan hospit jinxin
paid bn licenc price qualif licenc form
quit high barrier new privat hospit want enter ar industri
process licenc applic also long complex provinci health
commiss first discuss evalu necess build new ivf hospit
complet hospit construct employe train usual take
year mn organis evalu industri specialti
pass one-year test oper need well anoth round evalu
end test run approv formal oper evalu
perform everi two year continu regul therefor total
year lead time need establish new ivf hospit scratch
figur key process ivf licenc applic
appli ivf
organ
final approv
share grow
verifi
finish
must aih/aid
licens
suspend
result reput help jinxin occupi half sichuan ivf market
end hospit sichuan provinc own ivf licenc
popul hospit cover mn much higher
recommend mn sichuan provinc still huge undevelop market due
scarciti qualifi ar hospit ivf cycl perform
sichuan penetr rate jinxin fertil top ar hospit
sichuan market share
charl martineau univers toronto figur popul ivf hospit cover provinc
high market share partial contribut compani good reput
built long period jinxin patient come jinxin
hospit referr recommend acquaint requir littl
market expens believ compani continu leverag good reput
maintain lead posit sichuan
continu invest strengthen technolog edg
compani keep strengthen two barrier provid pgd/pg servic
indirectli hainan hospit medic elev success rate
upgrad pgd/pg technolog
get pgd/pg licenc key mileston jinxin help compani
stand competitor pgd/pg technolog improv ivf success rate
significantli patient might prefer pgd/pg screen
genet chromosom diseas embryo implant howev end
ivf hospit china pgd/pg technolog licenc get
pgd/pg licenc china difficult due follow two reason
strong regul chines govern concern use
pgd/pg sex select accord compani manag pay
attent hospit whose pgd/pg account total ivf
cycl mean challeng pass licenc re-evalu
limit indic perform pgd/pg china narrow indic
accord china pgd/pg expert consensu pgd/pg use
parent genet diseas clearly-known mutat posit patient
without indic ban use technolog china
besid get pgd/pg licenc compani own share hainan
cime boao ivf centr pgd/pg licenc compani subsidiari medic
also perform pgd/pg us whole platform compani provid
pgd/pg servic hospit hainan us self-own hospit
also leverag technolog know-how hospit
figur symposium hered reproduct
immunolog held shenzhen zhongshan hospit
compani keep invest achiev higher success rate top ar
hospit china citic-xiangya reproduct genet hospit achiev
success rate highest china believ jinxin catch
jinxin keep invest medic scientif research compani conduct
research hered reproduct immunolog main caus
habitu abort laboratori sichuan shenzhen breakthrough
field give compani competit edg elev ivf success rate
cut edg technolog use data analysi compani
investig appli machin learn analys larg amount clinic data
order develop computer-enhanc embryo analysi select scientist
also tri find correl among patient treatment method embryo physiolog
data ivf success rate order optimis treatment condit procedur
better ivf success rate
charl martineau univers toronto jinxin aim build
ivf cycl
success rate
occupi share
reach nation oversea market
commenc sichuan provinc jinxin fertil gradual copi busi
model region china compani also see huge market oversea ivf
servic chines coupl may gener synergi domest busi
eventu jinxin aim build global lead ar platform meet variou
unmet need infertil patient
domest expans acquir local lead
acquisit shenzhen zhongshan hospit success exampl
jinxin began expand busi region china first step
jinxin purchas share shenzhen zhongshan hospit januari
mn shenzhen zhongshan hospit licenc provid ar includ
aih ivf-et icsi right acquisit jinxin start implement
standardis oper procedur establish develop chengdu xinan
hospit shenzhen zhongshan hospit improv includ
renov zhongshan hospit facil enhanc patient experi
unlik sichuan provinc guangdong provinc shenzhen ar market
crowd hospit guangdong provinc ivf
licenc ivf hospit guangdong cover averag mn peopl
fourth number sichuan provinc guangdong also privat
ivf hospit ivf medic group ivf medic group own three ivf hospit
guangdong provinc perform ivf cycl
although competit market shenzhen zhongshan hospit still complet
ivf cycl success rate occupi share
guangdong ivf market shenzhen zhongshan hospit began provid
vip servic includ privat psycholog consult result averag price
singl ivf cycl shenzhen zhongshan hospit higher
price sichuan may collabor fudan univers hospit also
establish joint centr focus studi immunolog mechan
recurr spontan abort recurr implant failur
figur ivf centr shenzhen zhongshan
figur ivf patient cycl averag
price xinan shenzhen zhongshan
charl martineau univers toronto acquisit
hospit irr
evalu shenzhen zhongshan return assum achiev yoy
revenu growth stabl net profit margin forward price-to-earnings ratio price-to-earnings
around irr wacc indic
jinxin target ar
facil east china
beijing-tianjin-
hubei region build
 compani key strategi china busi expans
success acquisit shenzhen zhongshan hospit prove model futur
 china jinxin target ar facil east china beijing-tianjin-hubei
region first build nation-wid network compani plan find target
figur privat ivf hospit beijing-tianjin-hebei region
among ar hospit ivf licenc beijing-tianjin-hebei region
seven privat hospit might suitabl view three
foreign background ownershipbeij baodao healthcar taiwan tianjin
ufh amcar us notic potenti acquir target
market rel high qualiti alreadi built strong region reput
one hand acquisit hospit ensur strong foothold region
acquisit might expens
believ jinxin gain valuabl experi reput success
acquisit shenzhen zhongshan hospit china ivf jinxin replic
busi inject manag experi standardis practic new
acquir hospit proce bn rais ipo support
compani strategi help occupi market faster competitor
charl martineau univers toronto scarciti top ivf
tighter regul
china result
chines patient
tap oversea ar market
huge unmet need chines patient seek ivf servic oversea
chines patient seek ivf servic oversea higher servic
qualiti wider ivf choic customis servic chines patient went
abroad ivf servic went us sever
differ chines oversea ivf market
fewer top ivf hospit china us uneven medic
resourc lead crowd patient sever top ivf hospit citic-xiangya
hospit patient need wait least month enter ivf cycl
patient live region without top ivf hospit difficult receiv
conveni high-qual ivf treatment top-tier ivf hospit patient
bear poor servic environ
figur environ hospit
figur recept area medic
technolog gap still exist china us pgd/pg tech
perform ivf hospit china common us
huge unmet need pgd/pg tech china mani genet diseas
predict prevent tech pgd/pg tech high requir
laboratori physician ivf hospit china provid result
averag ivf success rate us also higher china
oversea ar hospit provid choic due differ regul
surrogaci frozen preserv eggs/sperm popular among chines coupl
seek oversea ar strictli partial forbidden china howev
servic legal us law develop countri protect
right patient surrog mother babi quit well california law even allow
name surrog mother intend parent birth certif better
figur comparison ar industri china us
legal state
one
us
acquisit medic open oversea market
establish medic could trace back provid ar
convent ivf-et icsi well pre-ivf treatment fertil problem
endometriosi fibroid block fallopian tube fertil rank first
us ar market ivf treatment cycl perform chines patient
import client fertil medic perform ivf
treatment cycl chines patient respect chines
patient repres total ivf treatment cycl perform medic
figur ivf patient cycl perform
figur number chines patient seek
gain capabl
global patient
especi
decemb jinxin fertil complet acquisit manag
manag medic manag establish novemb
manag servic organis render manag servic nine fertil
clinic medic provid manag
administr non-med servic necessari oper medic
return manag servic fee
acquisit jinxin fertil gain capabl provid high-valu ar
global patient especi china doctor china also recommend
medic high-end patient want treat us without intermediari
agent current cross-bord medic supplier play intermediari role
domest patient oversea hospit refer patient oversea ar
hospit receiv commiss fee patient hospit accord
compani around mn paid everi year move forward jinxin refer
chines patient intern without fee guarante streamlin
servic intern refer patient conveni servic provid
us china
charl martineau univers toronto figur busi model cross border ar china
financi perspect acquisit also add valu jinxin
compani purchas manag share swap equal mn
forward price-to-earnings ratio less estim keep stabl net profit margin
invest gener irr higher
wacc compani
synergi medic jinxin
acquisit medic open oversea ar market jinxin
also grant jinxin access advanc ar technolog best manag
procedur help foster brand china
academ commun jinxin doctor could help jinxin adopt
develop cut edg ar technolog oversea train opportun
provid jinxin domest medic profession improv technic skill
fertil well establish clinic protocol know-how also adopt jinxin
domest hospit improv overal clinic practic manag
addit hrc brand well recognis tier citi could help jinxin build
strong brand region ramp busi potenti tier citi
final hrc pgd/pg licenc rich experi could also help jinxin conduct
pgd/pg busi us potenti china obtain pgd/pg licenc
charl martineau univers toronto tp
potenti upsid
initi outperform tp
jinxin fertil list hong kong exchang june ipo price
sinc stock price fluctuat
believ leader china ar industri first ipo industri
jinxin benefit fast-grow ar market forecast
consolid fertil jinxin fertil gener
mn revenu
target price potenti upsid base multi-stag
discount cash flow dcf method weight averag cost capit wacc
perpetu growth gener revenu model sum
ivf servic revenu manag fee jinxin fertil hospit
number ivf cycl revenu expect
acquisit high-qual ivf hospit china us
posit polici ar industri
build revenu model sum direct revenu compani variou
hospit revenu hospit estim region infertil patient ivf
penetr rate penetr rate number ivf cycl averag price ivf
cycl also consid manag fee gener compani manag
servic certain proport revenu
assum penetr ivf patient china across differ age group would
increas current also assum xinan hospit
jinjiang hospit market share sichuan would slightli decreas
respect due region competit zhongshan hospit market share
expect doubl current also assum medic
would see steadi yoy increas chines patient futur
estim ivf revenu china assum jinxin would complet
acquisit two ar hospit around ivf cycl
also assum two new ar hospit would follow growth pattern
shenzhen zhongshan hospit reach ivf cycl five
charl martineau univers toronto figur revenu forecast jinxin fertil
ivf revenu china
ivf revenu china
gross margin compani gross margin long term
estim gross margin could gradual elev main reason includ
optimis medic process scale effect expans steadi price increas
benefit nation control drug price cost drug ivf may stabl
 expens estim expens mn
 expens elev due compani continu invest basic
clinic research method improv success rate long term estim
compani expens stabl total revenu keep
lead posit industri
sell market expens compani disclos sell expens
howev medic consolid estim compani
sell cost mn sell expens
commiss cross-bord medic supplier medic revenu
long term estim percentag may gradual declin
acquisit reduc relianc intermediari agent
capital-expenditure compani complet renov facil upgrad xinan
hospit shenzhen zhongshan hospit estim stabl routin capital-expenditure
consid potenti futur assum jinxin may complet two
mn respect
use multi-stag dcf model deriv compani valuat bn
tp assum wacc perpetu growth rate wacc
calcul assum equiti risk premium compani beta compani
complet ipo rais enough money equiti market believ
need rais money debt forese futur use compani beta
refer compani medic servic industri compar medic
servic provid beta consid jinxin still earli stage
expans franchis give compani beta
jinxin busi maintain stabl net profit good cash flow expect see
steadi increas net cash flow model except
assum two potenti mn would occur busi expans
capital-expenditure revenu
chang work capit
discount factor
npv cash-flow
npv tv
number share
also use valuat method justifi target price choos
ratio peer valuat exclud price-to-earnings ratio due compani high growth
rate next year jinxin p/e rel high
medic servic sector growth rate differ compani vari lot make price-to-earnings
ratio good indic
result ratio suitabl compani adjust ep growth rate
select medic servic compani list apac market chines compani list
hk/china market ivf hospit compar compani includ
comprehens hospit specialti clinic
methodolog tp repres within industri
averag select apac medic servic compani base
solid fundament situat compani believ tp justifi
jinxin data base cs model note price august
bloomberg professionaltm servic compani credit suiss estim jinxin fertil
sky/grey sky valuat
jinxin revenu forecast valuat highli subject ivf technolog
penetr rate jinxin market share ivf accept china may vari lot due
certain polici technolog develop therefor assum three
scenario sensit analysisbas case blue sky grey sky case blue sky
scenario elev penetr rate ivf tech infertil patient well
jinxin market share busi similarli lower two rate
grey sky scenario base scenario analysi blue sky valuat
grey sky valuat
figur revenu model three scenario
ivf revenu china
figur valuat deriv dcf model
npv cash-flow
npv tv
number share
risk stricter regulatori polici
ar industri china strong regul could influenc
compani busi china right regul hospit daili oper
licenc verif settlement medic disput etc regul chines us
ar compani becom stricter may increas compani oper cost
affect daili oper
risk get renew licenc
ar hospit must ivf licenc china compani oper subject
licenc permit requir well period audit inspect relev
author risk licenc suspens even loss pass
inspect busi could significantli affect perman close case
problem get renew licenc
reput crucial ar hospit directli affect patient choic jinxin
fertil good reput base high-qual servic high ivf success
rate patient-centr cultur howev compani reput could badli
affect medic accid manag flaw out-of-d technolog result
revenu profit may also affect
risk progress expect
 compani main expans strategi china leverag market
access acceler growth howev may difficult make deal potenti
target due expens price disagr detail process may also take
lot time manag effort compani resourc compani
progress slower target qualiti lower expect may affect jinxin
futur profit valuat
risk fiercer competit
ar industri china us fierc competit especi case privat
hospit public hospit china enjoy abund medic resourc tax-fre polici
govern support privat hospit china extens ar network
ampl financi resourc also strong competitor jinxin jinxin need
continu upgrad technolog servic maintain current lead posit
first gener test tube babi use embryo transfer refer egg
sperm need remov human bodi develop embryo vitro
embryo transfer back mother womb order achiev
compar natur combin process egg sperm ivf-et icsi need
physician inject sperm egg cell cytoplasm fertilis egg cell
cultur earli embryo final put back mother womb tech
introduc first use case sever male infertil
pgd pg use genet select screen test tube babi
pg screen ivf-creat embryo correct number chromosom
use one cell taken embryo pgd process involv examin
cell taken ivf-creat embryo specif genet defect
fertil declin gradual femal age quantiti qualiti oocyt
declin cytoplasm fertilis egg play import role earli stage egg
develop technolog human oocyt cytoplasm replac egg cell
nuclear transfer brought hope elderli women children
ordinari ivf treatment servic includ pre-ivf treatment stage ivf treatment
stage receiv care examin order confirm diagnos caus
infertil patient enter ivf treatment cycl usual last day
ivf cycl perform doctor offic clinic without hospitalis
patient want use egg ovari need stimul synthet
hormon produc multipl egg egg promis higher success rate
fertilis egg may develop normal drug may includ
medic ovarian stimul follicle-stimul hormon luteinis hormon
medic oocyt matur human chorion gonadotrophin medic
prevent prematur ovul medic prepar line uteru typic
ovarian stimul last two week egg readi retriev vagin
ultrasound blood test perform determin egg retriev
step egg sperm retriev
egg retriev usual perform transvagin ultrasound aspir within hour
final stimul drug inject multipl egg remov follicl
minut meantim sperm provid partner sperm bank
differ ivf-et icsi reflect step ivf-et healthi
sperm matur egg mix incub overnight icsi singl healthi
sperm inject directli matur egg fertilis egg cultur
vitro day embryo transfer assist hatch pgd/pg could also
provid physician need
fertilis egg develop appropri stage doctor transfer embryo
patient uteru cathet one embryo small amount fluid
inject cathet vagina cervix success embryo
implant line uteru day egg retriev test
blood sampl two week
jinxin senior manag team compos experienc expert china ar
industri ceo abund hospit manag experi china cfo
ivf professor work ivf tech consult china us
figur board director background
chairman non-
execut director
execut director
role respons
respons develop corpor strategi develop plan
respons overal manag busi develop
respons overal manag group overse oper
intern audit
respons manag clinic oper busi develop
north america
respons provid guidanc financi manag busi
develop group
respons provid guidanc corpor strategi govern
respons provid guidanc financi manag busi
develop group
supervis provid independ judgment board
supervis provid independ judgment board
supervis provid independ judgment board
supervis provid independ judgment board
role respons
execut director
respons overal manag busi develop
execut director
respons overal manag group overse oper
intern audit
respons overal manag group daili oper
implement merger acquisit
respons financi manag group member
compani financ activ investor relat manag
respons overal coordin standard qualiti control qualiti
insur technic improv group ivf clinic laboratori
develop group clinic embryologist train center
respons medic research develop group manag
shenzhen zhongshan hospit
respons implement intern develop strategi
intern merger acquisit manag manag
respons medic qualiti control compani manag
respons manag daili affair medic busi compani
respons overse complianc matter within group
sharehold corpor structur
figur principl sharehold jinxin ordinari share
number share
name owner
bloomberg professionaltm servic credit suiss research
figur corpor structur ipo
zeng yong
holt view jinxin fertil group
holt methodolog use proprietari perform measur known
return invest cfroi approxim econom return
estim averag real intern rate return earn firm portfolio
project constitut oper asset firm cfroi directli compar
real cost capit investor real discount rate see firm creat
econom wealth remov account inflat distort cfroi allow
global compar across sector region time comprehens metric
tradit roe
appli key cs analyst estim holt framework result
valuat scenario valuat initi use ten year key analyst estim drive
cfroi forecast proprietari algorithm determin rate fade toward
figur credit suiss analyst estim holt
compani mention price
